A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

• Conditions: Advanced Cancer
• Interventions: Drug: BMS-986205; Biological: Nivolumab

• Registration Number: NCT03792750
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-12-31
• Study First Submitted: 2019-01-02
• Study First Submitted QC: 2019-01-02
• Study First Posted: 2019-01-03
• Primary Completion: 2020-12-18
• Study Completion: 2020-12-18
• Results First Submitted: 2021-12-17
• Status Verified: 2022-02
• Results First Submitted QC: 2022-02-03
• Last Update Submitted: 2022-02-03
• Results First Posted: 2022-02-28
• Last Update Posted: 2022-02-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
• Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
• Participants must have an ECOG performance status of less than or equal to 1
• Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1

Read More

Exclusion Criteria

• Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
• Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
• Participants must not have a history of allergy to any of the study treatment components

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental Arm A	BMS-986205	2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
Experimental Arm A	Nivolumab	2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy

Primary Outcome Measures

Name	Time	Method
The Number of Participants Experiencing Adverse Events (AE)	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants experiencing adverse events (AEs) to assess the safety and tolerability of BMS-986205.; An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
The Number of Participants Experiencing Serious Adverse Events (SAE)	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants experiencing serious adverse events (SAEs) to assess the safety and tolerability of BMS-986205; Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Number of Participant Deaths	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants who died in each arm during the study to assess the safety and tolerability of BMS-986205.
The Number of Participants Experience Adverse Events (AE) Leading to Discontinuation	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants experiencing adverse events (AEs) leading to discontinuation to assess the safety and tolerability of BMS-986205; An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants with clinical laboratory test abnormalities based on US conventional units to assess the safety and tolerability of BMS-986205.; The number of subjects with the following laboratory abnormalities will be summarized: TSH \> ULN WITH TSH \<= ULN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE \< LLN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES \>= LLN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) TSH \< LLN WITH TSH \>= LLN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE \> ULN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES \<= ULN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date)
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests	From first dose to 100 days after last dose of study therapy (up to approximately 2 years)	The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units to assess the safety and tolerability of BMS-986205.; The number of participants with the following laboratory abnormalities will be summarized: ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN Total bilirubin \> 1.5 x ULN and 2 x ULN Concurrent (within 1 day) ALT or AST \> 3 x ULN with total bilirubin \> 2 x ULN Concurrent (within 30 days) ALT or AST \> 3 x ULN with total bilirubin \> 2 x ULN
(Cmax) Maximum Observed Plasma Concentration	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1	The maximum observes plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
(Tmax) Time of Maximum Observed Plasma Concentration	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1	The time of maximum observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
(AUC(TAU)) Area Under the Concentration-time Curve in One Dosing Interval	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1	The area under the concentration-time curve in one dosing interval was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
(CLT/F) Apparent Total Body Clearance	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1	The apparent total body clearance was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
(T-HALF (Eff, AUC)) Effective Elimination Half-life	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14	The effective elimination half-life was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. T-HALF (eff, AUC) explains the degree of AUC accumulation observed.
(AI_CMAX) Accumulation Index	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14	The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. AI is calculated based on ratio of Cmax at steady state to after the first dose.
(AI_AUC ) Accumulation Index	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14	The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. AI is calculated based on ratio of AUC(TAU) at steady state to after the first dose.
(Ctrough) Trough Observed Plasma Concentration	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1	The trough observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
(percentUR24) Percent Urinary Recovery Over 24 Hours	pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2	The percent urinary recovery over 24 hours was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.; BMS-986205 had minimal evaluable concentration in urine to derive the parameter.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	From first dose up to approximately 2 years	ORR is defined as the total number of participants whose best overall response (BOR) is either a completer response (CR) or partial response (PR) divided by the total number of participants in the population of interest. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator; BOR is defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy.
Best Overall Response (BOR)	From first dose up to approximately 2 years	BOR defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator
Duration of Response (DOR)	From first dose up to approximately 2 years	Duration of Response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator.
Measurement of Serum Kynurenine Levels	Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)	Measurement of kynurenine levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
Measurement of Tryptophan Levels	Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)	Measurement of tryptophan levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
Number of Participants With Anti-drug Antibodies (ADA) to Nivolumab	Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)	The number of participants with positive or negative anti-drug antibodies (ADA) to nivolumab was collected to characterize the immunogenicity of nivolumab when administered in combination with BMS-986205.; Baseline ADA Positive: A subject with baseline ADA-positive sample. ADA Positive: A subject with at least one ADA-positive sample relative to baseline.; Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline ADA Negative: A subject with no ADA-positive sample after initiation of treatment.

Trial Locations

Locations (1)

Local Institution; 🇨🇳 Hangzhou, Zhejiang, China